Monitoring of Epstein–Barr virus load in patients after allogeneic hematopoietic stem cell transplantation
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Infection |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1007/s15010-012-0262-5 |
| Field | Oncology and hematology |
| Keywords | Epstein–Barr virus; hematopoietic stem cell transplantation |
| Attached files | |
| Description | Based on our results, we recommend the weekly monitoring of patients for at least 3 months after HSCT (2 out of 4 patients with EBV-associated disease passed the cut-off at week 11) and longer in patients with GVHD, due to the rapid progression of EBV infection, particularly in patients who develop clinical symptoms (lymphadenopathy, hepatosplenomegaly, or organ manifestations) related to EBV disease according to the European Conference on Infections in Leukemia (ECIL) 2011 guidelines. EBV reactivation occurred in some of the patients suffering fromGVHDin this cohort, but did not require clinical intervention unless the copy numbers were steadily increasing. A stable EBV viral load\1,000 copies/lg DNA temporarily occurred in some patients after HSCT; however, clinical symptoms of EBV infection did not develop and they did not require therapeutic intervention. Therefore, to improve the diagnostic value of EBV monitoring, the load measurement and quantitative monitoring of viral load kinetics is necessary. |
| Related projects: |